Precision BioSciences Announces Clearance of Investigational New Drug Application by the US FDA for First-in-Class PBGENE-HBV Designed to Eliminate Root Cause of Chronic Hepatitis B

Precision BioSciences, Inc. announced that the US FDA has cleared the Investigational New Drug application for PBGENE-HBV. PBGENE-HBV is Precision’s lead wholly owned in vivo gene editing program designed to cure chronic hepatitis B by eliminating cccDNA